Yes, sickle cell disease is autosomal recessive. This means a child must inherit two copies of the altered gene, one from each parent, to develop the disease. The gene responsible sits on chromosome 11, which is not a sex chromosome, so sickle cell affects males and females equally.
What Autosomal Recessive Means in Practice
The term “autosomal” tells you the gene is on one of the 22 non-sex chromosomes. “Recessive” means one working copy of the gene is enough to keep you healthy. You only develop the disease when both copies carry a mutation.
Sickle cell disease traces to a single point mutation in the gene that provides instructions for making the beta chain of hemoglobin, the protein in red blood cells that carries oxygen. When both copies of this gene carry the mutation, your body produces an abnormal form of hemoglobin called hemoglobin S. This altered hemoglobin causes red blood cells to distort into a rigid, sickle shape, which can block small blood vessels and trigger episodes of severe pain, organ damage, and chronic anemia.
Carrier Parents and Inheritance Odds
When both parents carry one copy of the sickle gene (known as sickle cell trait), each pregnancy has these odds:
- 25% chance the child inherits two sickle genes and has sickle cell disease
- 50% chance the child inherits one sickle gene and becomes a carrier
- 25% chance the child inherits no sickle genes at all
These probabilities reset with every pregnancy. Having one child with the disease doesn’t change the odds for the next. A child can also develop sickle cell disease by inheriting one copy of hemoglobin S from one parent and a different hemoglobin mutation (such as one that causes thalassemia) from the other. These compound forms still follow a recessive pattern, requiring two faulty copies.
Sickle Cell Trait vs. Sickle Cell Disease
People with sickle cell trait carry one normal hemoglobin gene and one sickle hemoglobin gene. Their hemoglobin S levels typically stay below 35%, and their red blood cells look completely normal under a microscope at rest. Carriers are, for the most part, asymptomatic. They don’t experience the pain crises that define sickle cell disease, and their life expectancy matches the general population.
In rare situations, carriers can experience symptoms like blood in the urine or muscle breakdown during extreme exertion. Some report cramping, weakness, or a dull ache within minutes of intense physical activity due to reduced blood flow to muscles. But these episodes are uncommon and far milder than what people with the full disease face.
Sickle cell disease, by contrast, causes lifelong complications: chronic anemia, repeated pain crises from blocked blood vessels, organ damage over time, and significantly shortened lifespan without treatment. The difference between carrying one copy and carrying two copies of the gene is enormous, which is the hallmark of a recessive condition.
Why the Sickle Gene Is So Common
About 7.74 million people worldwide were living with sickle cell disease in 2021, with roughly 515,000 affected babies born each year. Nearly 80% of cases occur in sub-Saharan Africa. The gene is so prevalent in these regions because carrying one copy provides a significant survival advantage against malaria.
Malaria parasites invade red blood cells to grow and multiply. In carriers of sickle cell trait, the parasites have a harder time doing this. Infected red blood cells in carriers tend to sickle prematurely, which flags them for destruction by the spleen before the parasite can complete its life cycle. Research in a Kenyan population found that this protection actually increases over the first 10 years of life, suggesting the trait also helps the immune system learn to fight malaria more effectively. This “heterozygote advantage” is one of the most well-known examples in human genetics of natural selection maintaining a harmful gene in a population because the carrier state is beneficial.
How Sickle Cell Disease Is Diagnosed
In the United States and many other countries, every newborn is screened for sickle cell disease through a heel-prick blood test performed shortly after birth. The lab analyzes the types of hemoglobin in the sample using techniques that separate proteins by size and charge. If the screening comes back positive, a follow-up team will contact the family and retest to confirm.
Adults and older children who haven’t been screened can get a blood test that checks whether their body produces hemoglobin S and how much. Genetic testing can determine whether someone has one copy of the gene (carrier) or two copies (disease), which is especially useful when blood test results are ambiguous or when the person might carry a combination of different hemoglobin mutations.
Gene Therapy Now Targets the Root Cause
Because sickle cell disease stems from a single, well-understood gene mutation, it has become one of the first conditions treatable with gene therapy. In December 2023, the FDA approved two gene therapies for patients 12 and older who experience recurrent pain crises.
The first, Casgevy, uses CRISPR gene-editing technology to modify a patient’s own blood stem cells. Rather than fixing the sickle gene directly, it switches on production of fetal hemoglobin, a form of hemoglobin that babies naturally produce before birth. Fetal hemoglobin prevents red blood cells from sickling, essentially compensating for the defective adult hemoglobin. The second therapy, Lyfgenia, takes a different approach by inserting a gene that produces a modified hemoglobin functioning similarly to normal adult hemoglobin. In both cases, a patient’s stem cells are collected, modified in a lab, and transplanted back into the bone marrow.
These therapies represent a fundamental shift from managing symptoms to addressing the genetic root of the disease. They don’t change the fact that sickle cell disease is inherited recessively, but they offer the possibility of eliminating its effects in a person’s body even though they still carry both copies of the gene.